Physicians and healthcare providers specializing in lung cancer will come together for a multidisciplinary event focused on breaking down barriers that prevent nearly half of Minnesota’s eligible patients from receiving essential biomarker testing—testing that is key to......More
Physicians and healthcare providers specializing in lung cancer will come together for a multidisciplinary event focused on breaking down barriers that prevent nearly half of Minnesota’s eligible patients from receiving essential biomarker testing—testing that is key to determining the best possible treatment. Working Agenda Session 1: 8 a.m. Understanding Lung Cancer Biomarker Testing – Evolving U.S. Guidelines. Emilian Racila, MD, Anatomic and Clinical Pathologist, Associate Professor, University of Minnesota Medical School. Diana Oramas-Mogrovejo, MD, Assistant Professor, University of Minnesota Medical School. Session 2: 9:30 a.m. Practical Strategies to Overcome Barriers to Biomarker Testing for NSCLC Patients – Panel of physicians from healthcare systems serving Minnesotans living with lung cancer. Moderated by Aaron S. Mansfield, MD, Mayo ClinicNaomi Fujioka, MD, Medical Oncologist, Associate Professor, University of Minnesota Medical SchoolBob Kratzke, MD, Medical Oncologist, Professor, Department Chair, University of Minnesota Medical SchoolJoe Leach, MD, Medical Oncologist, Associate Medical Director, Quality and Safety, Allina Health Cancer InstituteYing-Chun Lo, MD, PhD, Pathologist, Mayo ClinicManish Patel, DO, Medical Oncologist, Associate Professor, University of Minnesota Medical SchoolJaime Schneider, MD, PhD, Medical Oncologist, Dana-Farber Cancer Institute, Harvard Medical SchoolAditi Singh, MD, MPH, Thoracic, Head & Neck Medical Oncologist, Minneapolis VA Healthcare System Assistant Professor of Medicine, University of MinnesotaDan Mundt, MD, Medical Oncology & Hematology, Minnesota OncologyOther speakers TBDSession 3: 11 a.m. The Value of Broad Panels that Capture Actionable and Non-Actionable Mutations (with tabletop discussions to follow) Working Through Reports on Actionable Lung Cancer Biomarkers/Available Targeted Therapies Understanding Non-actionable Mutations that may influence clinical decision making (i.e. TP53 in EGFR patients or STK11/KEAP1). Deepti Behl, MD, Mayo Clinic, formerly Chief of Oncology/Medical Director, Sutter Sacramento Lung Cancer ProgramBalancing rapid/targeted NGS panel testing and broad panels for quick results. Sarah Kerr, MD, Pathologist, Co-Vice President of Hospital Pathology Associates and Chair of the Department of Pathology at Abbott Northwestern Hospital, Allina HealthNetworking Lunch: 12:30-1:30 p.m. THANK YOU EXHIBITORS!PARTNER ASSOCIATE CONTRIBUTOR PATRONCaris Life Sciences Nuvation Bio PMV Pharmaceuticals Puma Biotechnology Regeneron Rigel Pharmaceuticals Tempus BREAKFAST SPONSORFoundation Medicine For sponsor or exhibitor information contact Emma Carper-Jacobo at 952-454-0648 or [email protected] We look forward to connecting!
Westin Edina Galleria, 3201 Galleria, Edina, 55345, United States
